The U.S. Patent and Trademark Office will be holding its next biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting on September 24, 2018 at the USPTO Headquarters (Alexandria, VA). The agenda for the meeting is as follows:
• Welcoming and Opening Remarks (10:00 - 10:10 am EDT) – Gary Jones, Daniel Sullivan, and Andrew Wang, Directors, TC1600, USPTO
• Obviousness of Biologics: Identifying the Biggest Challenges (10:10 - 11:00 am) -- Carla Mouta-Bellum of Arrigo, Lee, Guttman & Mouta-Bellum LLP
• Exemplary Obviousness Rationales Suggested in KSR (11:00 - 11:50 am) -- Lora Driscoll, QAS, TC1600, USPTO
• Lunch (11:50 am - 12:50 pm)
• 112(f)-New Form Paragraphs (12:50 - 1:40 pm) -- Marjorie Moran, QAS, TC1600, USPTO
• Requirements for Information Under 37 CFR 1.105 and Responses to Said Requirements (1:40 - 2:40 pm) -- Amjad Abraham, SPE, and Shubo (Joe) Zhou, SPE, TC1600, USPTO
• Break (2:40 - 3:00 pm)
• Accidental Infringement: the need for additional limitations in plant utility claims directed to chemical profiles or cultivars (3:00 - 3:50 pm) -- Reggie Gaudino, Chief Science Officer, Steep Hill Labs, Inc.
• Closing Remarks (3:50 - 4:00 pm) – Directors, TC1600, USPTO
Additional information regarding the BCP customer partnership meeting, including registration information for those wishing to attend the meeting or register for online participation, can be found here.
Comments